MX2019003694A - Metodos para tratar cancer del tracto biliar. - Google Patents
Metodos para tratar cancer del tracto biliar.Info
- Publication number
- MX2019003694A MX2019003694A MX2019003694A MX2019003694A MX2019003694A MX 2019003694 A MX2019003694 A MX 2019003694A MX 2019003694 A MX2019003694 A MX 2019003694A MX 2019003694 A MX2019003694 A MX 2019003694A MX 2019003694 A MX2019003694 A MX 2019003694A
- Authority
- MX
- Mexico
- Prior art keywords
- biliary tract
- methods
- treating biliary
- tract cancer
- effective amount
- Prior art date
Links
- 208000020790 biliary tract neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 201000009036 biliary tract cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 2
- 238000011284 combination treatment Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405706P | 2016-10-07 | 2016-10-07 | |
| PCT/US2017/055559 WO2018067943A1 (en) | 2016-10-07 | 2017-10-06 | Methods of treating biliary tract cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003694A true MX2019003694A (es) | 2019-06-24 |
Family
ID=61831977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003694A MX2019003694A (es) | 2016-10-07 | 2017-10-06 | Metodos para tratar cancer del tracto biliar. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200129469A1 (enExample) |
| EP (1) | EP3522887A4 (enExample) |
| JP (1) | JP2019529520A (enExample) |
| KR (1) | KR20190066033A (enExample) |
| AU (1) | AU2017340913A1 (enExample) |
| BR (1) | BR112019006329A2 (enExample) |
| CA (1) | CA3039582A1 (enExample) |
| MX (1) | MX2019003694A (enExample) |
| WO (1) | WO2018067943A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| SMT202100642T1 (it) | 2015-06-29 | 2022-03-21 | Abraxis Bioscience Llc | Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| IL292439B2 (en) | 2019-10-28 | 2026-05-01 | Abraxis Bioscience Llc | Pharmaceutical preparations of albumin and rapamycin |
| WO2022140261A1 (en) * | 2020-12-22 | 2022-06-30 | Ambys Medicines, Inc. | Biliary delivery methods, compositions and kits for use therein |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3051495A1 (en) * | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| CA2801891C (en) * | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| CA2964155A1 (en) * | 2014-10-10 | 2016-04-14 | Idera Pharmaceuticals, Inc. | Treatment of cancer using tlr9 agonist with checkpoint inhibitors |
-
2017
- 2017-10-06 CA CA3039582A patent/CA3039582A1/en not_active Abandoned
- 2017-10-06 KR KR1020197012517A patent/KR20190066033A/ko not_active Ceased
- 2017-10-06 EP EP17859266.3A patent/EP3522887A4/en not_active Withdrawn
- 2017-10-06 JP JP2019518506A patent/JP2019529520A/ja active Pending
- 2017-10-06 US US16/338,900 patent/US20200129469A1/en not_active Abandoned
- 2017-10-06 MX MX2019003694A patent/MX2019003694A/es unknown
- 2017-10-06 AU AU2017340913A patent/AU2017340913A1/en not_active Abandoned
- 2017-10-06 BR BR112019006329A patent/BR112019006329A2/pt not_active Application Discontinuation
- 2017-10-06 WO PCT/US2017/055559 patent/WO2018067943A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20200129469A1 (en) | 2020-04-30 |
| EP3522887A1 (en) | 2019-08-14 |
| EP3522887A4 (en) | 2020-06-10 |
| AU2017340913A1 (en) | 2019-04-18 |
| KR20190066033A (ko) | 2019-06-12 |
| CA3039582A1 (en) | 2018-04-12 |
| JP2019529520A (ja) | 2019-10-17 |
| WO2018067943A1 (en) | 2018-04-12 |
| BR112019006329A2 (pt) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| MX2017016491A (es) | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). | |
| MY162903A (en) | Methods of treatment of pancreatic cancer | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| NZ746554A (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| MX364637B (es) | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. | |
| BR112019006329A2 (pt) | métodos de tratamento de câncer do trato biliar | |
| BR112012024349A2 (pt) | métodos de tratamento de carcinoma hepatocelular | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| IL257670A (en) | Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer |